recurrent pneumonia: recurrent pneumonia due to nontuberculous mycobacterium infections
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
407 |
4. Check minimum number of eventsNone |
407 |
5. Include endpointsNone |
407 |
6. Filter based on genotype QC (FinnGen only) |
407 |
Control definitions (FinnGen only)
- Control exclude
- ASTHMA_PNEUMONIA
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- A31
- Name in latin
- Infectio pulmonalis mycobacterialis
Similar endpoints
↥List of similar endpoints to
Atypical mycobacterium lung infection
based on the number of shared cases.
Similar with more cases:
- Pneumonias (Asthma/COPD co-morbidities)
- COPD/asthma/ILD related pneumonia or pneumonia derived septicaemia
- COPD/asthma related pneumonia or pneumonia derived septicaemia
- COPD/asthma related infections
- COPD/asthma/ILD related infections
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3018 | 1576 | 1387 |
| Only index persons | 2203 | 1277 | 926 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.05 | 0.04 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 68.38 | 71.46 | 64.83 |
| Only index persons | 67.81 | 70.61 | 63.93 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 407 | 225 | 182 |
| Unadjusted period prevalence (%) | 0.08 | 0.08 | 0.08 |
| Median age at first event (years) | 67.20 | 65.95 | 68.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 347
- Matched controls
- 3468
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A31.0
ICD-10 Finland
Pulmonary mycobacterial infection
+∞
323.0
328
*
J47
ICD-10 Finland
Bronchiectasis
63.8
101.2
116
27
UGC12
NOMESCO Finland
Flexible bronchoscopy
20.8
98.3
157
132
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
16.9
93.5
165
176
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
26.7
90.9
130
76
R03BB04
ATC
tiotropium bromide; inhalant
14.6
79.6
148
168
R03AK06
ATC
salmeterol and fluticasone; inhalant
11.0
68.5
149
222
J18.9
ICD-10 Finland
Pneumonia, unspecified
8.0
67.6
210
560
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
9.0
65.0
165
317
J01MA14
ATC
moxifloxacin; systemic
11.3
54.8
112
140
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
25.2
50.0
71
35
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
14.3
45.4
80
71
J45.9
ICD-10 Finland
Asthma, unspecified
6.9
45.3
133
288
TGC00
NOMESCO Finland
Bronchial lavation
24.2
44.7
64
32
J01MA12
ATC
levofloxacin; systemic
5.7
41.6
149
407
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
7.4
39.6
105
192
R03AC12
ATC
salmeterol; inhalant
15.7
39.4
66
51
R03DA04
ATC
theophylline; systemic, rectal
11.1
39.2
78
88
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.6
38.6
237
1111
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
8.0
37.8
93
151
J45.0
ICD-10 Finland
Predominantly allergic asthma
10.1
36.2
76
94
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
12.1
35.5
67
67
R03AC02
ATC
salbutamol; inhalant
4.4
35.4
250
1287
J45.1
ICD-10 Finland
Nonallergic asthma
11.1
34.9
69
76
A31.9
ICD-10 Finland
Mycobacterial infection, unspecified
+∞
33.9
32
*
GD1AD
NOMESCO Finland
Thorax CT examination
12.6
33.6
62
59
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
3.8
30.0
226
1151
H02AB06
ATC
prednisolone; systemic
3.8
29.9
227
1162
R04.2
ICD-10 Finland
Haemoptysis
12.8
29.3
53
48
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
16.8
29.2
47
32
R03DC03
ATC
montelukast; oral
5.3
28.5
98
239
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
33.3
27.8
36
12
R03BA05
ATC
fluticasone; inhalant
4.4
25.5
108
324
R03AC03
ATC
terbutaline; inhalant
4.8
25.1
95
254
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.1
24.2
113
369
A15.0
ICD-10 Finland
Tuberculosis of lung, confirmed by sputum microscopy with or without culture
256.9
24.0
24
*
J01FA06
ATC
roxithromycin; oral
3.2
23.0
189
947
H02AB04
ATC
methylprednisolone; systemic
4.4
22.2
90
255
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
7.3
22.1
55
87
R03AK03
ATC
[D] fenoterol & other drugs for obstructive airway dis; inhalant
6.4
20.8
57
103
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.5
19.0
42
55
H02AB07
ATC
prednisone; oral
3.8
18.6
88
283
J96.1
ICD-10 Finland
Chronic respiratory failure
15.5
18.5
30
21
R03BA01
ATC
beclometasone; inhalant
3.9
18.4
85
267
R03BA02
ATC
budesonide; inhalant
3.6
18.2
95
328
3101A
ICD-9 Finland
Specific nonpsychotic mental disorders following organic brain damage, Organic personality syndrome
+∞
17.9
17
*
B44.1
ICD-10 Finland
Other pulmonary aspergillosis
189.2
17.7
18
*
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
6.7
17.4
45
75
R03BB01
ATC
ipratropium bromide; inhalant
6.5
17.2
46
80
R03AK08
ATC
formoterol and beclometasone; inhalant
9.4
16.9
35
41
R03AC13
ATC
formoterol; inhalant
6.5
16.2
43
74
J46
ICD-10 Finland
Status asthmaticus
12.6
15.9
28
24
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
27.8
15.8
21
8
J01AA02
ATC
doxycycline; systemic
3.1
15.7
293
2204
R81
ICPC
Pneumonia
9.6
15.3
31
35
XG410
NOMESCO Finland
Flow-volume spirometry
6.9
14.7
37
59
J45.8
ICD-10 Finland
Mixed asthma
14.4
13.9
23
17
TDM10
NOMESCO Finland
Puncture of maxillary antrum
8.3
13.7
30
39
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
8.4
13.4
29
37
J45
ICD-10 Finland
Asthma
4.2
13.3
52
139
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.0
12.6
81
319
SPAT1017
SPAT
Examination of colour vision
+∞
12.6
12
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
4.9
12.1
40
90
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.3
11.8
158
930
R03AL08
ATC
vilanterol, umeclidinium bromide and fluticasone furoate; inhalant
31.2
11.7
15
5
J01FA09
ATC
clarithromycin; systemic
2.4
11.7
120
616
J22
ICD-10 Finland
Unspecified acute lower respiratory infection
5.8
11.7
33
62
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
7.9
11.7
26
35
A16.0
ICD-10 Finland
Tuberculosis of lung, bacteriologically and histologically negative
123.9
11.5
12
*
A02BC02
ATC
pantoprazole; systemic
2.3
11.4
245
1779
R02
ICPC
Shortness of breath/dyspnoea
3.1
11.2
66
244
R03DC01
ATC
zafirlukast; oral
12.5
11.0
19
16
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
22.3
10.8
15
7
R05
ICD-10 Finland
Cough
2.6
10.8
88
399
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.4
10.7
115
603
A15.1
ICD-10 Finland
Tuberculosis of lung, confirmed by culture only
+∞
10.5
10
*
348
Kela drug reimbursment
Roflumilast
+∞
10.5
10
*
A31.80
ICD-10 Finland
Oral infection caused by Mycobacterium intracellulare
+∞
10.5
10
*
A31.89
ICD-10 Finland
Other mycobacterial infections
+∞
10.5
10
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.5
10.3
49
155
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
4.0
10.2
41
112
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
6.4
10.2
26
43
R03BA08
ATC
ciclesonide; inhalant
3.8
10.1
43
124
R06.0
ICD-10 Finland
Dyspnoea
2.3
10.0
112
592
R95
ICPC
Chron obstructive pulmonary disease
8.5
10.0
21
26
R50.9
ICD-10 Finland
Fever, unspecified
2.9
10.0
64
250
R03BB02
ATC
oxitropium bromide; inhalant
20.8
9.9
14
7
R01AD09
ATC
mometasone; nasal
2.1
9.8
157
977
R03AK07
ATC
formoterol and budesonide; inhalant
2.6
9.8
75
327
J01CA04
ATC
amoxicillin; systemic
2.3
9.7
271
2126
R03AK11
ATC
formoterol and fluticasone; inhalant
7.9
9.6
21
28
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
4.8
9.4
31
70
R03DX07
ATC
roflumilast; oral
+∞
9.4
9
*
J01GB01
ATC
tobramycin; inhalant, parenteral
+∞
9.4
9
*
4859X
ICD-9 Finland
Bronchopneumonia, organism unspecified[PNEUMONIA NUD]
9.9
9.4
18
19
J01FA10
ATC
azithromycin; systemic
2.0
9.2
193
1327
J02AC01
ATC
fluconazole; systemic
2.1
9.2
137
820
J41.1
ICD-10 Finland
Mucopurulent chronic bronchitis
37.7
9.1
11
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
9.0
121
693
GAA10
NOMESCO Finland
Intercostal insertion of pleural drainage tube
8.3
9.0
19
24
A01AB04
ATC
amphotericin B; local oral
4.2
8.9
33
84
R01AD08
ATC
fluticasone; nasal
2.2
8.8
105
571
J02AC03
ATC
voriconazole; systemic
51.3
8.7
10
*
A03
ICPC
Fever
2.7
8.6
60
246
UDH02
NOMESCO Finland
Rhinopharyngoscopy
3.8
8.4
35
100
J20
ICD-10 Finland
Acute bronchitis
3.1
8.3
47
169
R05
ICPC
Cough
2.2
8.3
96
513
J01FA15
ATC
telithromycin; oral
3.1
8.1
45
159
XQ800
NOMESCO Finland
Prick test
3.8
7.9
33
94
49300
ICD-8 Finland
Asthma, bronchiale
7.2
7.9
18
26
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
11.2
7.9
14
13
J40
ICD-10 Finland
Bronchitis, not specified as acute or chronic
6.6
7.8
19
30
R24
ICPC
Haemoptysis
18.9
7.6
11
6
4912B
ICD-9 Finland
Chronic bronchitis, Obstructive chronic bronchitis[BRONCHITIS OBSTRUCTIVA CUM EMPHYSEMATE]
18.9
7.6
11
6
1240
FHL
Bronchoscopy
10.4
7.6
14
14
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
2.0
7.4
128
796
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.3
7.4
77
389
R05DA20
ATC
opium alkaloids and derivatives - combinations
2.1
7.3
97
546
0310A
ICD-9 Finland
Diseases due to other mycobacteria, Pulmonary
+∞
7.3
7
*
J15.1
ICD-10 Finland
Pneumonia due to Pseudomonas
+∞
7.3
7
*
M05BA04
ATC
alendronic acid; oral
2.7
7.3
52
215
XG474
NOMESCO Finland
Exhalation nntrogen oxide
7.6
7.3
16
22
A07AA02
ATC
nystatin; oral
3.3
7.2
35
113
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
5.8
7.2
19
34
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.4
7.1
33
103
WW200
NOMESCO Finland
Immunization
5.1
6.8
20
41
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
8.1
6.7
14
18
SPAT1255
SPAT
Intravenous administration of medicine
3.2
6.6
33
110
B44.0
ICD-10 Finland
Invasive pulmonary aspergillosis
71.1
6.4
7
*
E84.0
ICD-10 Finland
Cystic fibrosis with pulmonary manifestations
+∞
6.3
6
*
A15.2
ICD-10 Finland
Tuberculosis of lung, confirmed histologically
+∞
6.3
6
*
4226
FHL
Posterior radical surgery and possible etmoidectomy
27.2
6.3
8
*
L04AA06
ATC
mycophenolic acid; systemic
7.9
6.2
13
17
J44
ICD-10 Finland
Other chronic obstructive pulmonary disease
7.9
6.2
13
17
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.2
144
983
A01AB09
ATC
miconazole; local oral
2.7
6.1
42
171
WX892
NOMESCO Finland
Monitored bed care
2.9
6.0
35
129
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
165
101
26.79
208.36
10.1
3.0
—
—
—
0
0
93
29
41.27
148.25
13.4
2.9
—
—
—
0
0
61
17
42.03
99.22
2.0
1.3
1.8
0.1
u/ml
—
44
8
73
47
18.71
86.74
1.8
1.6
—
—
—
0
0
78
59
16.12
85.10
1.8
1.6
—
—
—
0
0
81
72
13.80
80.23
3.0
1.3
—
—
—
0
0
59
34
20.13
73.62
1.3
1.2
—
—
—
0
0
62
47
15.38
67.10
1.6
1.6
—
—
—
0
0
64
52
14.42
66.54
1.6
1.6
—
—
—
0
0
98
161
7.70
60.21
2.1
1.2
181.7
280.5
u/ml
0.29
92
147
49
31
17.83
58.15
2.1
1.5
—
—
—
0
0
60
9
77.82
53.86
16.3
5.4
—
—
—
0
0
37
21
19.28
46.01
2.5
1.9
2827.2
484.6
e6/l
0.61
24
11
62
85
8.43
44.07
2.4
1.6
—
—
—
0
0
59
82
8.25
41.39
2.5
1.6
—
—
—
0
0
50
62
9.05
38.41
2.7
1.6
—
—
—
0
0
154
552
3.88
36.45
3.0
1.8
—
—
—
0
0
30
18
17.91
36.17
1.7
1.2
—
—
—
0
0
24
11
23.12
32.42
1.6
1.4
—
—
—
0
0
26
21
13.16
26.59
1.9
1.6
—
—
—
0
0
34
41
8.96
26.50
2.7
1.5
—
—
—
0
0
24
17
14.94
26.42
2.0
1.6
—
—
—
0
0
24
18
14.11
25.59
2.0
1.6
—
—
—
0
0
23
16
15.18
25.54
3.3
2.6
15.8
10.6
%
—
10
10
38
56
7.38
25.06
5.5
3.0
5.1
4.3
e9/l
0.94
38
56
291
1809
3.14
24.49
19.5
8.8
4.9
4.1
e9/l
4.35
279
1576
38
60
6.88
23.52
5.6
3.6
62.6
57.8
%
1.26
38
60
21
15
14.71
22.94
2.2
1.9
—
—
—
0
0
21
15
14.71
22.94
2.2
1.9
—
—
—
0
0
21
15
14.71
22.94
2.2
1.9
—
—
—
0
0
21
15
14.71
22.94
2.2
1.9
—
—
—
0
0
127
522
3.08
22.67
7.7
3.3
0.8
0.8
mmol/l
0.33
122
485
20
15
13.97
21.23
3.8
2.7
—
—
—
0
0
76
242
3.63
20.38
1.7
1.6
—
—
—
0
0
25
29
9.12
19.98
2.2
1.7
—
—
—
0
0
25
29
9.12
19.98
2.2
1.7
—
—
—
0
0
25
29
9.12
19.98
2.2
1.7
—
—
—
0
0
17
11
16.08
19.46
2.4
2.2
—
—
—
0
0
17
11
16.08
19.46
2.4
2.2
—
—
—
0
0
99
383
3.09
19.33
2.7
1.8
—
—
—
0
0
32
52
6.59
19.22
2.7
1.5
—
—
—
0
0
17
12
14.74
18.58
2.5
2.1
—
—
—
0
0
268
1754
2.55
17.64
13.4
6.1
9.0
11.2
umol/l
7.85
259
1651
96
384
2.96
17.54
2.8
1.8
—
—
—
0
0
33
61
5.80
17.43
1.8
1.2
—
—
—
0
0
33
61
5.80
17.43
1.8
1.2
—
—
—
0
0
33
62
5.70
17.13
14.4
7.0
152.8
154.1
iu/ml
—
6
10
50
136
4.05
16.69
3.5
1.8
—
—
—
0
0
64
207
3.48
16.62
5.7
3.4
1.8
1.9
mmol/l
0.10
51
160
25
37
7.13
16.32
2.7
1.6
—
—
—
0
0
25
38
6.94
15.93
2.7
1.6
—
—
—
0
0
22
29
7.96
15.84
2.1
1.6
—
—
—
0
0
38
91
4.50
14.94
2.2
1.5
0.2
0.1
iu/ml
—
5
18
255
1723
2.29
14.27
9.9
6.3
1.2
1.2
mmol/l
0.02
208
1431
45
127
3.86
14.23
2.8
1.6
—
—
—
0
0
37
91
4.37
14.06
1.9
1.5
—
—
—
0
0
235
1575
2.16
12.90
8.9
5.6
1.2
1.2
mmol/l
0.12
225
1391
310
2399
2.23
10.75
11.6
4.1
19.3
13.3
mm/h
6.37
301
2173
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
33
93
3.77
10.43
3.4
2.2
0.4
0.4
u/ml
0.31
20
51
25
62
4.23
9.38
1.4
1.3
—
—
—
0
0
14
9
16.05
9.09
1.4
1.1
—
—
—
0
0
25
65
4.03
8.82
2.6
2.3
15.6
15.8
%
0.04
13
33
208
1472
1.84
8.39
5.8
4.5
32.8
35.3
g/l
5.91
192
1369
16
30
5.51
8.27
1.0
1.1
—
—
—
0
0
63
292
2.37
8.22
1.6
2.4
64.6
65.8
g/l
0.47
53
262
49
203
2.61
8.11
2.3
1.7
—
—
—
0
0
23
64
3.75
7.41
1.9
2.2
122.6
129.6
g/l
0.51
15
49
23
64
3.75
7.41
1.3
1.1
—
—
—
0
0
132
848
1.82
7.01
2.5
2.1
3.2
3.2
mg/l
0.04
119
710
181
1283
1.74
6.83
3.0
2.7
118.6
130.7
ug/l
0.46
170
1148
10
6
17.04
6.77
3.0
1.3
—
—
—
0
0
88
505
1.95
6.59
1.2
1.3
90.4
40.0
iu/ml
0.56
29
154
146
985
1.75
6.48
4.6
3.1
33.0
32.5
u/l
0.04
141
938
307
2545
1.84
6.48
18.3
7.3
81.1
80.1
u/l
0.16
302
2362
17
42
4.18
6.42
2.1
1.9
89.4
90.0
%
0.16
17
42
159
1107
1.72
6.27
3.4
3.1
1362.1
1434.2
ng/l
0.11
142
937
245
1925
1.69
6.05
7.8
4.8
6.5
6.8
mmol/l
1.13
237
1795
89
531
1.87
5.88
2.6
2.4
12.0
12.5
umol/l
0.31
83
482
212
1612
1.66
5.87
3.2
2.6
—
—
—
0
0
73
409
1.96
5.82
9.3
5.2
1.0
1.1
mmol/l
0.69
68
371
29
113
2.69
5.43
1.7
2.3
0.7
0.4
g/l
0.19
24
95
54
281
2.06
5.28
3.7
3.0
182.9
187.5
ng/l
0.04
49
250
30
124
2.53
5.01
1.7
2.0
3.5
3.3
g/l
0.70
23
96
64
364
1.90
4.86
5.3
7.7
2.9
1.2
mmol/l
2.47
54
287
104
685
1.70
4.84
2.5
1.6
1.3
1.3
mg/l
0.05
83
544
31
134
2.42
4.72
1.6
2.0
—
—
—
0
0
31
134
2.42
4.72
1.6
2.0
3.7
3.8
g/l
0.10
23
95
31
134
2.42
4.72
1.6
2.0
8.0
7.6
g/l
0.38
24
97
75
462
1.76
4.40
2.8
2.4
18.7
21.9
%
1.64
66
393
77
478
1.75
4.40
2.8
2.4
2.3
2.3
g/l
0.23
71
440
29
126
2.40
4.38
1.7
2.0
9.6
10.3
g/l
0.41
23
105
7
6
11.84
4.29
1.1
1.0
97.9
95.3
%
—
7
6
7
6
11.84
4.29
1.1
1.0
—
—
—
0
0
27
115
2.44
4.26
1.3
3.2
—
2.8
—
0
11
27
116
2.42
4.18
1.4
3.3
32.9
28.3
mg/l
0.39
20
84
27
116
2.42
4.18
1.4
3.3
232.6
122.4
mg/l
0.24
19
84
279
3144
0.64
3.98
5.5
5.3
2.5
2.7
mmol/l
1.40
249
2829
130
948
1.55
3.89
5.7
3.1
0.3
0.5
e6/l
0.72
111
716
16
54
3.04
3.89
1.1
1.3
—
—
—
0
0
8
11
7.39
3.87
4.4
1.5
24.4
30.6
umol/l
—
8
11
173
1348
1.49
3.76
5.3
4.0
74.6
68.4
ng/l
0.04
135
1019
9
16
5.73
3.67
2.4
2.7
628.7
805.2
u/ml
—
9
16
94
651
1.58
3.49
1.3
1.3
1.3
1.7
u/ml
0.37
18
155
72
472
1.64
3.35
1.3
1.3
18.3
11.5
u/ml
0.16
15
165
151
1167
1.47
3.33
4.6
3.3
2.3
2.4
mmol/l
1.07
135
1003
13
43
3.09
3.28
1.8
1.3
—
—
—
0
0
14
50
2.86
3.11
1.3
1.2
—
—
—
0
0
156
1227
1.44
3.09
5.6
3.2
—
—
—
0
0
54
337
1.69
3.02
8.3
3.3
3.2
2.1
mmol/l
1.11
48
256
57
361
1.67
3.02
5.8
3.5
—
—
—
0
0
139
1074
1.45
3.02
3.1
2.4
53.4
57.4
u/l
0.94
133
989
117
875
1.47
3.01
1.5
1.6
19.6
21.5
nmol/l
0.73
102
717
17
69
2.53
3.00
2.4
1.4
—
—
—
0
0
170
1368
1.42
2.94
2.7
2.2
84.2
77.8
nmol/l
2.30
151
1178
92
659
1.51
2.91
4.5
3.9
442.3
259.8
ng/l
0.47
74
546
6
9
6.75
2.87
1.0
1.1
—
—
—
0
0
277
3065
0.70
2.78
5.1
4.7
4.5
4.6
mmol/l
0.16
243
2772
11
37
3.03
2.71
1.1
1.1
—
—
—
0
0
13
49
2.71
2.65
1.2
1.2
125.0
102.2
u/ml
—
5
10
9
25
3.66
2.59
1.4
1.2
—
—
—
0
0
12
44
2.78
2.57
1.2
1.1
—
—
—
0
0
276
3041
0.71
2.53
5.0
4.7
1.6
1.5
mmol/l
3.51
244
2732
21
102
2.12
2.52
1.5
1.2
—
—
—
0
0
7
16
4.43
2.48
1.3
1.4
—
—
—
0
0
7
16
4.43
2.48
1.3
1.4
—
—
—
0
0
280
3071
0.72
2.42
5.3
4.9
5.9
6.0
mmol/l
1.41
253
2734
271
2980
0.73
2.30
6.2
6.3
40.4
40.5
mmol/mol
0.04
251
2731
7
18
3.94
2.26
1.3
1.5
—
—
—
0
0
5
10
5.05
2.07
10.4
2.5
—
—
—
0
0
11
45
2.48
1.94
1.5
1.5
—
—
—
0
0
8
27
3.00
1.94
1.1
1.3
—
—
—
0
0
8
27
3.00
1.94
1.1
1.3
—
—
—
0
0
6
16
3.79
1.94
1.5
1.6
—
—
—
0
0
6
16
3.79
1.94
1.5
1.6
—
—
—
0
0
8
28
2.89
1.87
1.5
1.3
—
—
—
0
0
94
732
1.37
1.87
1.8
1.8
1330.7
1199.2
nmol/l
0.60
70
527
103
814
1.36
1.86
4.8
2.8
3848.5
7674.1
umol/l
0.47
97
681
11
47
2.38
1.79
1.5
1.5
—
—
—
0
0
11
47
2.38
1.79
1.5
1.5
—
—
—
0
0
11
47
2.38
1.79
1.5
1.5
—
—
—
0
0
11
47
2.38
1.79
1.5
1.5
—
—
—
0
0
10
41
2.48
1.76
1.4
1.1
1.4
1.5
u/ml
—
5
11
10
41
2.48
1.76
1.2
1.1
—
—
—
0
0
6
18
3.37
1.75
1.3
1.5
—
—
—
0
0
6
18
3.37
1.75
1.2
1.8
—
—
—
0
0
5
13
3.88
1.72
3.8
1.7
83.0
72.8
ug/l
—
5
13
11
48
2.33
1.72
1.5
1.5
—
—
—
0
0
75
571
1.38
1.71
4.3
2.8
0.8
1.3
e6/l
1.03
50
338
86
670
1.36
1.70
2.7
3.1
2.5
2.5
mmol/l
1.55
75
588
271
2937
0.77
1.69
4.4
4.2
1.2
1.3
mmol/l
2.77
235
2617
17
91
1.91
1.63
2.2
1.5
—
—
—
0
0
51
371
1.43
1.51
3.1
2.9
6.0
8.9
umol/l
0.94
46
329
99
803
1.31
1.49
3.4
2.3
—
—
—
0
0
9
37
2.46
1.49
2.8
2.2
—
—
—
0
0
43
305
1.46
1.46
2.2
2.5
32.2
32.4
u/l
0.02
37
251
262
2399
1.26
1.42
4.4
3.9
15.1
14.9
pmol/l
0.31
238
2116
7
29
2.44
1.40
3.1
2.9
—
—
—
0
0
30
199
1.55
1.39
1.7
1.3
—
—
—
0
0
167
1459
1.25
1.36
2.1
2.0
94.1
95.3
pmol/l
0.12
95
728
124
1051
1.26
1.31
2.8
2.1
122.1
199.3
u/l
2.35
119
973
5
18
2.80
1.29
1.0
1.0
—
—
—
0
0
62
483
1.33
1.24
33.5
23.8
1.6
1.2
inr
0.99
14
66
12
63
1.93
1.24
2.2
2.7
28.8
27.8
mg/l
—
5
22
16
93
1.75
1.23
2.9
2.8
118.1
109.8
ug/min
—
10
58
52
398
1.35
1.17
1.3
1.4
—
—
—
0
0
7
30
2.36
1.13
1.0
1.2
—
—
—
0
0
67
539
1.29
1.08
4.8
3.0
2.5
2.9
e6/l
0.16
43
309
21
137
1.56
1.08
2.0
1.3
—
—
—
0
0
64
788
0.78
1.06
3.9
4.5
19.3
21.7
%
0.69
29
407
42
317
1.36
1.05
2.0
2.6
8.1
7.4
ug/l
0.10
34
276
328
3126
1.25
1.02
40.6
15.2
23.8
23.9
mg/l
0.04
307
2502
5
23
2.19
0.98
1.0
1.1
—
—
—
0
0
210
1924
1.19
0.97
7.1
3.1
48.2
51.4
u/l
0.23
198
1772
58
714
0.78
0.97
4.5
4.7
1.0
1.0
kg/l
0.50
17
99
13
77
1.71
0.96
1.4
1.3
—
—
—
0
0
34
257
1.35
0.86
3.1
2.8
74.7
59.1
ml/min/173m2
1.36
17
105
9
151
0.59
0.80
1.4
3.2
29.3
2027.5
u/ml
—
9
131
12
75
1.62
0.75
1.1
1.4
—
—
—
0
0
15
101
1.50
0.71
1.7
1.2
—
—
—
0
0
11
69
1.61
0.69
1.0
1.2
—
—
—
0
0
5
27
1.86
0.68
2.2
1.4
—
—
—
0
0
15
103
1.47
0.66
1.7
1.2
—
—
—
0
0
51
428
1.22
0.62
14.1
6.0
103.0
103.9
mmol/l
0.85
51
418
36
441
0.80
0.61
8.2
7.4
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
48
569
0.82
0.60
3.3
3.1
1.0
0.8
ug/l
0.19
35
388
88
779
1.17
0.60
1.7
1.7
460.0
9677866.5
pmol/l
0.50
70
620
97
1079
0.87
0.57
5.7
3.9
10.1
10.4
mg/mmol
0.02
72
660
8
55
1.46
0.56
1.4
1.7
—
—
—
0
0
14
99
1.43
0.55
1.6
1.6
—
—
—
0
0
89
991
0.87
0.54
5.8
5.2
3.1
3.1
ug/l
0.02
74
878
6
39
1.55
0.53
1.3
1.1
—
—
—
0
0
6
40
1.51
0.52
5.7
4.0
29.6
37.4
u/ml
—
6
40
13
94
1.40
0.46
3.3
1.7
—
—
—
0
0
96
877
1.12
0.43
6.0
4.6
0.0
0.0
estimate
0.00
49
299
116
1252
0.90
0.43
6.1
4.5
—
—
—
0
0
33
390
0.83
0.42
1.4
1.4
—
—
—
0
0
9
67
1.35
0.38
1.0
1.2
—
33.4
—
0
7
19
152
1.26
0.37
1.0
1.0
—
—
—
0
0
11
81
1.37
0.36
1.3
1.3
—
—
—
0
0
5
76
0.65
0.36
1.2
1.5
118.2
238.8
pmol/l
—
5
76
91
839
1.11
0.35
1.7
1.6
1.3
1.3
mmol/l
0.40
76
683
10
74
1.36
0.32
1.1
1.1
—
13.1
—
0
8
302
2956
1.08
0.27
30.8
14.7
78.6
75.0
ml/min/173m2
2.38
278
2423
14
171
0.81
0.26
1.5
1.7
—
—
—
0
0
5
73
0.68
0.26
1.6
1.6
—
—
—
0
0
9
75
1.20
0.25
1.0
1.3
—
—
—
0
0
9
76
1.19
0.25
1.6
1.2
—
—
—
0
0
49
447
1.11
0.24
4.3
4.7
36.7
32.1
%
1.98
38
276
20
171
1.18
0.23
1.4
1.4
—
33.7
—
0
13
5
39
1.29
0.23
1.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
349.3
—
0
7
296
2909
1.06
0.20
5.4
4.8
1.9
2.4
mu/l
0.67
271
2588
16
186
0.85
0.19
1.2
1.2
75.4
144.2
iu/ml
—
8
66
164
1587
1.06
0.19
5.4
4.2
0.0
0.0
estimate
0.00
50
310
7
58
1.21
0.18
1.6
1.6
28.8
20.0
iu/l
—
7
49
8
69
1.16
0.16
1.4
1.9
—
—
—
0
0
164
1605
1.04
0.11
7.3
5.7
0.0
0.0
estimate
0.00
52
302
5
45
1.11
0.10
1.4
1.6
—
—
—
0
0
165
1619
1.03
0.09
5.5
4.2
0.0
0.0
estimate
0.00
50
294
6
58
1.03
0.08
1.2
1.2
21.8
18.0
u/l
—
6
48
5
61
0.82
0.08
1.2
1.2
1.2
0.8
nmol/l
—
5
49
154
1516
1.03
0.07
4.5
4.2
—
—
—
0
0
273
2722
1.01
0.01
33.9
16.4
38.4
39.2
%
0.69
167
1780
15
148
1.01
0.00
2.0
1.8
—
—
—
0
0
16
162
0.99
0.00
5.8
2.9
40.1
57.7
u/ml
0.31
16
157
16
161
0.99
0.00
1.9
2.0
—
—
—
0
0
5
49
1.02
0.00
1.6
1.3
0.5
0.6
nmol/l
—
5
44
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.9
—
1.2
—
0
8
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
1.4
1.7
174.2
246.2
pmol/l
—
5
46
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint MYCOBLUNGATYPICA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| MYCOBLUNGATYPICA | 1.744 [1.51, 2.02] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.209 |
During the follow-up period (1.1.1998 — 31.12.2019), 571 out of 1246 females with MYCOBLUNGATYPICA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| MYCOBLUNGATYPICA | 3.148 [2.47, 4.01] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 490 out of 842 males with MYCOBLUNGATYPICA died.
Mortality risk
Mortality risk for people of age
years, who have MYCOBLUNGATYPICA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.123% | 0.602% |
| 5 | 0.936% | 3.554% |
| 10 | 2.477% | 8.216% |
| 15 | 5.023% | 15.414% |
| 20 | 8.501% | 25.509% |
Relationships between endpoints
↥Index endpoint: MYCOBLUNGATYPICA – Atypical mycobacterium lung infection
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data